2019 Early Detection Mid-Year Roundup, Part III: Clinical Performance and Economics

The shocking conclusion to a series on advances in early detection liquid biopsy from 2019H1:

  1. Part I: Tumor fraction still matters
  2. Part II: Technical advances from Grail and Guardant
  3. Part III: Clinical Performance and Economics

In the previous installments of this series, I’ve briefly reviewed some of the key …

Featured on Tech Tonics Podcast

Many thanks to Lisa Suennen and David Shaywitz for having me on Tech Tonics recently! My interview with them came out today. Listen to it on Connected Social Media or through your podcast app.

In it, I discuss with Lisa and David my work in computational biology, genetics, and the …

2019 Early Detection Mid-Year Roundup, Part II: Technology

Part of a series on advances in early detection liquid biopsy from 2019H1:

  1. Part I: Tumor fraction still matters
  2. Part II: Technical advances from Grail and Guardant

With the data I reviewed in the first post in the series it seems fair to say that everyone’s now agreed that …

Mid-2019 Early Detection Roundup, Part I: Tumor Fraction

The first half of the year is always exciting in the cancer world between results presented at AACR in April and ASCO in June, making it a good time to review the state of early detection science in mid-2019. This is long, so I’ll break it up into a …

Barriers to Entry and Barriers to Validation

(See the slides here)

In the final section of my recent keynote address for Cancer Research UK‘s 2019 Symposium on Oesophageal Cancer, I departed from my usual rants on technical rigor in science to discuss the political barriers that keep us from effectively translating and scaling new diagnostics in …